Anonymous
Guest
Anonymous
Guest
Ever heard of Fresenius? Look em up and ask Baxter what happened to their Renal marketshare of 80% back in 1990s.
Baxter owned the market. Not anymore
Baxter owned the market. Not anymore
As rust Blue belt/Blue states decline, BIO's growth in the west and southwest are encouraging. BIO's future non CRM pipeline is much stronger than many realize. Take a tour of the German plant and ask Euro MD's who has some of the best stents and drug eluting ballons in the vascular space
Get your myopia looke at too, CRM pays the bills at all of our competitors yet the growth moving forward is not CRM. Look at Boston's efforts in non CRM markert in terms of acquisitions. SJM and Big blue as well.
Do your homework on what things will look like circa 2015-17. I did and that's why BIO is in great shape and I signed on a few months back.
You could be looking at a company that could DOUBLE in revenue in 4-5 years
As rust Blue belt/Blue states decline, BIO's growth in the west and southwest are encouraging. BIO's future non CRM pipeline is much stronger than many realize. Take a tour of the German plant and ask Euro MD's who has some of the best stents and drug eluting ballons in the vascular space
Get your myopia looke at too, CRM pays the bills at all of our competitors yet the growth moving forward is not CRM. Look at Boston's efforts in non CRM markert in terms of acquisitions. SJM and Big blue as well.
Do your homework on what things will look like circa 2015-17. I did and that's why BIO is in great shape and I signed on a few months back.
You could be looking at a company that could DOUBLE in revenue in 4-5 years
Ever heard of Fresenius? Look em up and ask Baxter what happened to their Renal marketshare of 80% back in 1990s.
Baxter owned the market. Not anymore
As rust Blue belt/Blue states decline, BIO's growth in the west and southwest are encouraging. BIO's future non CRM pipeline is much stronger than many realize. Take a tour of the German plant and ask Euro MD's who has some of the best stents and drug eluting ballons in the vascular space
Get your myopia looke at too, CRM pays the bills at all of our competitors yet the growth moving forward is not CRM. Look at Boston's efforts in non CRM markert in terms of acquisitions. SJM and Big blue as well.
Do your homework on what things will look like circa 2015-17. I did and that's why BIO is in great shape and I signed on a few months back.
You could be looking at a company that could DOUBLE in revenue in 4-5 years